Wedbush reiterated their outperform rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research note published on Wednesday morning, Benzinga reports. Wedbush currently has a $152.00 target price on the stock. NBIX has been the topic of a number of other research reports. Canaccord Genuity Group lifted their price target on shares […]
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) were down 5.3% on Wednesday . The stock traded as low as $132.58 and last traded at $133.02. Approximately 153,432 shares were traded during trading, a decline of 81% from the average daily volume of 812,679 shares. The stock had previously closed at $140.48. Analyst […]
Westfield Capital Management Co. LP decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 8.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 594,437 shares of the company’s stock after selling 54,855 shares during the period. Westfield Capital Management Co. LP […]
Great Lakes Advisors LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 163,485 shares of the company’s stock after purchasing an additional 1,528 shares during the period. Great Lakes Advisors LLC owned about 0.17% […]